Medical/Pharmaceuticals
Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa
A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO, June 26, 2025 /PRNewswire/ -- Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, andEVA Pharma, one of the leading pharmaceutical compan...
Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals
BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
* Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has ...
5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa
NEW YORK, June 25, 2025 /PRNewswire/ -- On June 1, Dimora Medical, a continuous innovator in high-end medical care supplies, proudly participated as a sponsor in the HS Connect5K Walk. This event served not only as a fundraising effort but also as an opportunity for education about Hidradenitis S...
Medeologix Sets New Standard with 3-Week Lead Time for PET Heat Shrink Tubing
SAN JOSE, Calif., June 25, 2025 /PRNewswire/ -- Medeologix, a leading brand in medical device manufacturing, today announced a significant advancement in their production capabilities that slashes lead times for premium PET heat shrink tubing to just 3 weeks. This milestone is made possible by M...
Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr.Benny T. Hu. The company delivered updates on its ongoing drug development programs, outl...
EDAN Establishes Mexico Subsidiary to Strengthen Presence in the Americas
MEXICO CITY, June 25, 2025 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ), a healthcare company and medical device manufacturer, officially celebrated the opening of its new subsidiary, EDAN MEDICAL MÉXICO S de R.L. de C.V., with a ribbon-cutting ceremony held last Wednesday inMexico City. Th...
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
PanBrain Tech Unveils Breakthrough Brain-Computer Interface Device at BEYOND EXPO 2025 in Macau
MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain
Tech Co., Ltd.
OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer
PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment ofDimitry S.A. Nuyten, M.D.,...
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for...
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY * Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled h...
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative
oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today
announced the first US patient has started treatment in the ongoing Phase 1
trial (SIM0500-101,NCT06375044
MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®
TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI
Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
Strategic appointments reflect Medison's continued investment in global scale
and operational excellence
PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison
Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near...
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40